Development of DNA and viral vector vaccines against Epstein-Barr virus-positive nasopharyngeal carcinoma
Dr Lin, Chen-Lung (Principal investigator)
Professor Austyn Jonathan M. (Co-Investigator)
Dr Xu Xiaoning (Co-Investigator)
RGC General Research Fund (GRF)
HKU Project Code
General Research Fund (GRF)
To design and parpare DNA vaccine encoding EBNA1 and LMP2, and the MVA vaccine encoding the cytokine GM-CSF, the chemokine RANTES, the EBV- specific lytic antigen EBNA-1, and EBV-specific latent antigen LMP2; to identify the efficacy of these vaccines in vitro on their capacity in attracting dendritic cells and also in the induction of EBNA-1 specific CD4+T cell response and LMP2-specific CTL immunity; to verify the efficacy of these vaccines in a mouse NPC and a B cell lymphoma model, including the potency of CD4+ and CTL immunity, and also to test the effect of the dosage, route, and the effect of combinational use of both the DNA and MVA vaccines.